Khan Siddiqui - Dec 22, 2021 Form 4 Insider Report for Hyperfine, Inc. (HYPR)

Role
CMO and Chief Strategy Officer
Signature
/s/ John P. Condon, Attorney-in-Fact
Stock symbol
HYPR
Transactions as of
Dec 22, 2021
Transactions value $
$0
Form type
4
Date filed
12/23/2021, 08:46 PM
Next filing
Feb 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HYPR Stock Option (right to buy) Award +105K 105K Dec 22, 2021 Class A Common Stock 105K $3.76 Direct F1, F2, F3
transaction HYPR Stock Option (right to buy) Award +130K 130K Dec 22, 2021 Class A Common Stock 130K $3.76 Direct F4, F5
transaction HYPR Stock Option (right to buy) Award +54K 54K Dec 22, 2021 Class A Common Stock 54K $3.27 Direct F6, F7
transaction HYPR Stock Option (right to buy) Award +1.8K 1.8K Dec 22, 2021 Class A Common Stock 1.8K $5.24 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal
F2 (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in connection with the Mergers in exchange for a stock option to acquire 320,000 shares of Hyperfine common stock for $1.23 per share.
F3 The shares underlying this option vested as to 25% on December 31, 2020, with the remainder of the options vesting in equal monthly installments, over the following three years, subject to Dr. Siddiqui's continued service on each vesting date.
F4 Received in connection with the Mergers in exchange for a stock option to acquire 398,000 shares of Hyperfine common stock for $1.23 per share.
F5 The shares underlying this option vested as to 25% on December 31, 2020, with the remainder of the options vesting in equal monthly installments, over the following three years, subject to Dr. Siddiqui's continued service on each vesting date.
F6 Received in connection with the Mergers in exchange for a stock option to acquire 165,000 shares of Hyperfine common stock for $1.23 per share.
F7 The shares underlying this option vest in forty eight equal monthly installments beginning on January 31, 2021, subject to Dr. Siddiqui's continued service through the applicable vesting date.
F8 Received in connection with the Mergers in exchange for a stock option to acquire 10,000 shares of Liminal common stock for $0.94 per share.
F9 The shares underlying this option vest in forty eight equal monthly installments beginning on October 31, 2020, subject to Dr. Siddiqui's continued service through the applicable vesting date.